Market Overview

Immunomedics Awarded US Patent for Antibody-SN-38 Conjugates

Immunomedics (Nasdaq: IMMU) today announced the issuance of U.S. patent no. 8,617,558 for additional claims under the patent family "Camptothecin-binding moiety conjugates," and U.S. patent no. 8,617,518 with additional claims for the patent family "Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules."

Patent 8,617,558 relates to our proprietary linker technology for conjugating SN-38 to the Company's humanized antibodies for targeted delivery of the potent drug to the tumor. The patent will expire in December 2023. Additional patents covering the Company's antibody-drug conjugates are being prosecuted in major countries worldwide.

See full press release

Posted-In: News Guidance Legal Management Global


Most Popular

Related Articles (IMMU)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free